title: Serum heart type fatty acid binding protein levels in metabolic syndrome.
abstract: Heart type fatty acid binding protein (H-FABP) is a major cytoplasmic low-molecular weight protein and released into the circulation when the myocardium is injured. Previous studies have demonstrated that H-FABP is closely associated with acute coronary syndrome, hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism. The aim of this study was to investigate serum H-FABP value in the patients with metabolic syndrome (MetS). We measured serum H-FABP levels in 55 consecutive patients with MetS, and 73 age-matched control subjects by using a sandwich enzyme-linked immunosorbent assay. Serum H-FABP levels were significantly higher in patients with MetS than in control subjects 18.37 ± 13.0 and 7.9 ± 6.5 ng/ml, respectively, (P < 0.001). Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 ± 10.2 and 13.9 ± 12.6 ng/ml, respectively, (P: 0,003). There were statistically significant differences between patients without diabetic MetS and control subjects, 13.8 ± 12.6 and 7.9 ± 6.5 ng/ml, respectively, (P = 0.023). Patients with MetS have an increased risk of death from cardiovascular diseases. H-FABP seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in patients with MetS.
authors.affiliation: Department of Internal Medicine, Ankara Education and Research Hospital, Ministry of Health, Ankara, Turkey. erdem_akbal@mynet.com
authors.forename: Erdem
authors.initials: E
authors.lastname: Akbal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Özbek
authors.forename: Fahri
authors.initials: F
authors.lastname: Güneş
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Akyürek
authors.forename: Kemal
authors.initials: K
authors.lastname: Üreten
authors.forename: Tuncay
authors.initials: T
authors.lastname: Delibaşı
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000209:etiology; D016022:Case-Control Studies; D048909:Diabetes Complications / Q000097:blood / Q000453:epidemiology; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000032:analysis / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000453:epidemiology; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications / Q000453:epidemiology; D008875:Middle Aged
chemical_list: D015415:Biomarkers; C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins